Treatment of Aortic Stenosis in Patients Aged 70 or Older with a Tricuspid Aortic Valve
Clinical scenario
This protocol addresses adults aged 70 years or older presenting with severe aortic stenosis, a tricuspid (native three-leaflet) aortic valve, and anatomy that is suitable for a transcatheter approach.
Key patient characteristics
- Age ≥70 years
- Tricuspid aortic valve
- Suitable anatomy for transcatheter aortic valve implantation
- Severe aortic stenosis
Treatment approach
In this population, a transcatheter-based intervention is the recommended primary treatment modality. The full structured regimen — including access-route considerations, eligibility criteria, and clinical pathway — is available in the complete protocol.
Full regimen and clinical decision pathway available via the button below.
References
DOI: 10.1093/eurheartj/ehaf194
- TAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable.
- TAVI is recommended as the primary treatment modality in elderly patients ≥70 years of age with a tricuspid AV, if anatomy is suitable and transfemoral access is feasible, to reduce the risk of early adverse outcomes and accelerate recovery.
View source ↗